Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K, Vollenweider J, Han J, Staudinger N, Stenson M, Bayraktar L, Wellik LE, Maurer MJ, McPhail ED, Witzig TE, et al. Hematol Oncol. 2024 Jan; 42(1):e3233. Epub 2023 Oct 24.